TL;DR
This Phase II study investigated a bi-weekly combination of pemetrexed and irinotecan as a second-line treatment for metastatic colorectal cancer (mCRC) patients who had previously received FOLFOX chemotherapy. While the regimen showed activity with a 13.6% response rate and was generally well-tolerated, it did not appear to offer a significant clinical advantage over historical data for other standard second-line treatments like FOLFIRI.
What Problem Does This Paper Address?
Colorectal cancer remains a significant cause of cancer-related deaths, with a substantial portion of patients developing metastatic disease. For those with advanced mCRC, first-line chemotherapy regimens like FOLFOX (combining fluorouracil, leucovorin, and oxaliplatin) have improved outcomes, often leading to median survival exceeding 20 months. However, the clinical benefit of second-line therapy after FOLFOX failure remains a challenge, with limited options and often unsatisfactory response rates. Specifically, irinotecan-based regimens in this setting have historically shown response rates of only 5-10%. This study aimed to explore a novel bi-weekly pemetrexed plus irinotecan combination as a potential improved second-line option for these heavily pretreated patients.
Methods
This was an open-label, single-arm, two-stage Phase II study. Patients received pemetrexed (400 mg/m²) intravenously over 10 minutes, followed by irinotecan (180 mg/m²) intravenously over 90 minutes, administered on day 1 of a 14-day cycle. This regimen was continued for a maximum of 12 cycles. To mitigate potential toxicities associated with pemetrexed, patients received oral folic acid supplementation daily and intramuscular vitamin B12 injections every 9 weeks. Dexamethasone was also administered orally around each pemetrexed dose.
The primary endpoint was the objective response rate (ORR), defined by RECIST criteria, with a target of at least 20% for the regimen to be considered worthy of further study. Secondary endpoints included duration of response, progression-free survival (PFS), overall survival (OS), and toxicity profiles. Toxicity was graded using the NCI-CTCAE criteria.
Datasets
Not discussed in the paper. The study involved patient recruitment and treatment within clinical centers.
Key Insights and Ideas
- Novel Combination in a Challenging Setting: The study explored a less common bi-weekly schedule for pemetrexed and irinotecan, aiming to improve efficacy in the difficult-to-treat second-line mCRC setting.
- Importance of Supportive Care: The inclusion of folic acid and vitamin B12 supplementation highlights the critical role of supportive care in managing antifolate-based therapies and their associated toxicities.
- Benchmarking Against Historical Data: The study's conclusion hinges on comparing its results to historical data for other second-line regimens, underscoring the challenge of establishing superiority in single-arm trials.
- Potential for Subgroup Identification: The authors briefly touch upon the impact of genetic polymorphisms (TS and MTHFR) on pemetrexed activity, suggesting a future direction for personalized treatment.
Key Results
- Response Rate: Out of 44 evaluable patients, 6 achieved a partial response, resulting in an overall response rate (ORR) of 13.6% (95% CI, 5.2% to 27.4%). This met the study's threshold for further investigation.
- Disease Control: 18 patients (40.9%) had stable disease, and 15 patients (34.1%) had progressive disease.
- Survival: The median progression-free survival (PFS) was 4.0 months, and the median overall survival (OS) was 13.9 months.
- Toxicity: The most common grade 3-4 toxicities included fatigue (20.5%), neutropenia (18.6%), and diarrhea (13.6%). Overall, the regimen was considered active and well-tolerated.
Limitations and Future Work
- Single-Arm Design: The study's single-arm nature limits definitive conclusions about the regimen's superiority over existing treatments. Direct comparison with historical data is inherently less robust than randomized controlled trials.
- Limited Advantage: The authors conclude that the bi-weekly pemetrexed plus irinotecan regimen, while active and tolerable, does not appear to offer a clinically relevant advantage over historical data for classical FOLFIRI regimens in the second-line mCRC setting.
- Future Directions: The authors suggest that further research could focus on:
- Investigating combinations of pemetrexed with targeted drugs.
- Identifying patient subgroups who might benefit more from pemetrexed-based therapy, potentially through genomic profiling (e.g., TS and MTHFR polymorphisms).
- Exploring alternative schedules or combinations to potentially improve efficacy or manage toxicities.
- Considering this regimen for patients who experience severe toxicities with fluoropyrimidines or have contraindications to them.
Summary updated